← Back to Bills
H.R. 7640House117th Congress (2021-2023)In Committee

To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").

Sponsored by Gus M. BilirakisRep. Gus M. Bilirakis (R-FL)
Introduced May 3, 2022

AI-Generated Summary

Updated February 8, 2026 at 11:06 AM UTC

The bill updates the Orphan Drug Act to extend the federal grant and contract program that supports the development of orphan drugs. It changes the authorized period from 2018‑2022 to 2023‑2027, allowing continued funding for research on treatments for rare diseases. This affects drug developers, researchers, and patients with rare conditions who rely on these incentives.

Key Provisions

  • Amends Section 5(c) of the Orphan Drug Act to replace the date range "2018 through 2022" with "2023 through 2027", thereby reauthorizing the grant and contract program for orphan drug development for the new five‑year period.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action
HouseIntro Referral Latest Action

Referred to the House Committee on Energy and Commerce.

Energy and Commerce Committee

May 3, 2022

View full timeline
HouseIntro Referral

Introduced in House

May 3, 2022

HouseIntro Referral

Referred to the House Committee on Energy and Commerce.

Energy and Commerce Committee

May 3, 2022

Bill Text

Latest available legislative text

Reading Mode
Latest
Raw Text PDF XML
Introduced in HouseIssued May 3, 2022

I

117th CONGRESS

2d Session

H. R. 7640

IN THE HOUSE OF REPRESENTATIVES

May 3, 2022

Mr. Bilirakis (for himself and Mr. Butterfield) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as orphan drugs).

1.

Reauthorization of grants and contracts for development of orphan drugs

Section 5(c) of the Orphan Drug Act (21 U.S.C. 360ee(c)) is amended by striking 2018 through 2022 and inserting 2023 through 2027.